(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.)
Little known Toronto, Canada-based Cynapsus Therapeutics (OTCQX:CYNAF) is one of our best ideas for investment in the small-cap biotechnology sector. The company currently trades with a market capitalization of only $30 million, yet sits on a potential $750 million drug for the treatment of Parkinson's disease. The leading drug is APL-130277, a sublingual formulation of apomorphine, designed as a rescue medication for patients experiencing "off" time in-between their daily Levodopa dosing. Apomorphine is a highly effective drug, already approved in the U.S. and around the...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: